Search | VHL Search Portal

1.

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

Lee, Sylvia M; Moon, James; Redman, Bruce G; Chidiac, Tarek; Flaherty, Lawrence E; Zha, Yuanyuan; Othus, Megan; Ribas, Antoni; Sondak, Vernon K; Gajewski, Thomas F; Margolin, Kim A.

Cancer ; 121(3): 432-440, 2015 Feb 01.

Article in English | MEDLINE | ID: mdl-25250858

2.

New options for the adjuvant treatment of cutaneous melanoma?

Weise, Amy M; Flaherty, Lawrence E.

Curr Oncol Rep ; 16(11): 409, 2014 Nov.

Article in English | MEDLINE | ID: mdl-25286906

3.

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Sosman, Jeffrey A; Moon, James; Tuthill, Ralph J; Warneke, James A; Vetto, John T; Redman, Bruce G; Liu, P Y; Unger, Joseph M; Flaherty, Lawrence E; Sondak, Vernon K.

Cancer ; 117(20): 4740-06, 2011 Oct 15.

Article in English | MEDLINE | ID: mdl-21455999

4.

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Livingston, Robert B; Barlow, William E; Kash, Joseph J; Albain, Kathy S; Gralow, Julie R; Lew, Danika L; Flaherty, Lawrence E; Royce, Melanie E; Hortobagyi, Gabriel N.

Breast Cancer Res Treat ; 130(1): 123-31, 2011 Nov.

Article in English | MEDLINE | ID: mdl-21826527

5.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

Tarhini, Ahmad A; Kang, Ni; Lee, Sandra J; Hodi, F Stephen; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriet M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M.

J Immunother Cancer ; 9(5)2021 05.

Article in English | MEDLINE | ID: mdl-33963015

6.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Tarhini, Ahmad A; Lee, Sandra J; Hodi, F Stephen; Rao, Uma N M; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriett M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M.

J Clin Oncol ; 38(6): 567-575, 2020 02 20.

Article in English | MEDLINE | ID: mdl-31880964

7.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Clark, Joseph I; Singh, Jatinder; Ernstoff, Marc S; Lao, Christopher D; Flaherty, Lawrence E; Logan, Theodore F; Curti, Brendan; Agarwala, Sanjiv S; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L; Aung, Sandra; Lawson, David H.

J Immunother Cancer ; 6(1): 76, 2018 07 27.

Article in English | MEDLINE | ID: mdl-30053905

8.

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski, Wolfram E; Moon, James; Witter, Merle; Atkins, Michael B; Kirkwood, John M; Othus, Megan; Ribas, Antoni; Sondak, Vernon K; Flaherty, Lawrence E.

Cancer Med ; 6(11): 2576-2585, 2017 Nov.

Article in English | MEDLINE | ID: mdl-28994212

9.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki; Rao, Uma N; Tarhini, Ahmad A; Cohen, Gary I; Reintgen, Douglas S; Evans, Terry L; Brell, Joanna M; Albertini, Mark R; Atkins, Michael B; Dakhil, Shaker R; Conry, Robert M; Sosman, Jeffrey A; Flaherty, Lawrence E; Sondak, Vernon K; Carson, William E; Smylie, Michael G; Pappo, Alberto S; Kefford, Richard F; Kirkwood, John M.

J Clin Oncol ; 35(8): 885-892, 2017 Mar 10.

Article in English | MEDLINE | ID: mdl-28135150

10.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott, David F; Regan, Meredith M; Clark, Joseph I; Flaherty, Lawrence E; Weiss, Geoffery R; Logan, Theodore F; Kirkwood, John M; Gordon, Michael S; Sosman, Jeffrey A; Ernstoff, Marc S; Tretter, Christopher P G; Urba, Walter J; Smith, John W; Margolin, Kim A; Mier, James W; Gollob, Jared A; Dutcher, Janice P; Atkins, Michael B.

J Clin Oncol ; 23(1): 133-41, 2005 Jan 01.

Article in English | MEDLINE | ID: mdl-15625368

11.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Sosman, Jeffrey A; Unger, Joseph M; Liu, P-Y; Flaherty, Lawrence E; Park, Min S; Kempf, Raymond A; Thompson, John A; Terasaki, Paul I; Sondak, Vernon K.

J Clin Oncol ; 20(8): 2067-75, 2002 Apr 15.

Article in English | MEDLINE | ID: mdl-11956267

12.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

Sondak, Vernon K; Liu, P-Y; Tuthill, Ralph J; Kempf, Raymond A; Unger, Joseph M; Sosman, Jeffrey A; Thompson, John A; Weiss, Geoffrey R; Redman, Bruce G; Jakowatz, James G; Noyes, R Dirk; Flaherty, Lawrence E.

J Clin Oncol ; 20(8): 2058-66, 2002 Apr 15.

Article in English | MEDLINE | ID: mdl-11956266

13.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Budd, George T; Barlow, William E; Moore, Halle C F; Hobday, Timothy J; Stewart, James A; Isaacs, Claudine; Salim, Muhammad; Cho, Jonathan K; Rinn, Kristine J; Albain, Kathy S; Chew, Helen K; Burton, Gary V; Moore, Timothy D; Srkalovic, Gordan; McGregor, Bradley A; Flaherty, Lawrence E; Livingston, Robert B; Lew, Danika L; Gralow, Julie R; Hortobagyi, Gabriel N.

J Clin Oncol ; 33(1): 58-64, 2015 Jan 01.

Article in English | MEDLINE | ID: mdl-25422488

14.

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

Sondak, Vernon K; Flaherty, Lawrence E.

Lancet ; 372(9633): 89-90, 2008 Jul 12.

Article in English | MEDLINE | ID: mdl-18620932

15.

Biochemotherapy of melanoma.

Flaherty, Lawrence E; Gadgeel, Shirish M.

Semin Oncol ; 29(5): 446-55, 2002 Oct.

Article in English | MEDLINE | ID: mdl-12407509

16.

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

Tuthill, Ralph J; Unger, Joseph M; Liu, P Y; Flaherty, Lawrence E; Sondak, Vernon K.

Am J Clin Pathol ; 118(4): 504-11, 2002 Oct.

Article in English | MEDLINE | ID: mdl-12375635

17.

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.

Carson, William E; Unger, Joseph M; Sosman, Jeffrey A; Flaherty, Lawrence E; Tuthill, Ralph J; Porter, Mark J; Thompson, John A; Kempf, Raymond A; Othus, Megan; Ribas, Antoni; Sondak, Vernon K.

Cancer Immunol Res ; 2(10): 981-7, 2014 Oct.

Article in English | MEDLINE | ID: mdl-24994597

18.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B; Tuthill, Ralph J; Thompson, John A; Vetto, John T; Haluska, Frank G; Pappo, Alberto S; Sosman, Jeffrey A; Redman, Bruce G; Moon, James; Ribas, Antoni; Kirkwood, John M; Sondak, Vernon K.

J Clin Oncol ; 32(33): 3771-8, 2014 Nov 20.

Article in English | MEDLINE | ID: mdl-25332243

19.

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

Margolin, Kim A; Moon, James; Flaherty, Lawrence E; Lao, Christopher D; Akerley, Wallace L; Othus, Megan; Sosman, Jeffrey A; Kirkwood, John M; Sondak, Vernon K.

Clin Cancer Res ; 18(4): 1129-37, 2012 Feb 15.

Article in English | MEDLINE | ID: mdl-22228638

20.

ACCO: ASCO core curriculum outline.

Muss, Hyman B; Von Roenn, Jamie; Damon, Lloyd Earl; Deangelis, Lisa Marie; Flaherty, Lawrence E; Harari, Paul M; Kelly, Karen; Kosty, Michael P; Loscalzo, Matthew J; Mennel, Robert; Mitchell, Beverly S; Mortimer, Joanne E; Muggia, Franco; Perez, Edith A; Pisters, Peter W T; Saltz, Leonard; Schapira, Lidia; Sparano, Joseph.

J Clin Oncol ; 23(9): 2049-77, 2005 Mar 20.

Article in English | MEDLINE | ID: mdl-15728218

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export: